妊娠期非严重高血压疾病与口服降压药:反对使用的论据
妊娠期高血压疾病约占所有妊娠的13%。美国妇产科医师学会基于缺乏1级证据及理论风险,反对对妊娠期高血压和无严重特征的子痫前期使用降压药。CHAP试验显示治疗非严重慢性高血压有益后,出现了「适应证蔓延」,作者认为在缺乏确定性试验前广泛使用可能有害,亟需开展确定性试验。
要点
- 妊娠期高血压疾病约占所有妊娠的13%,是全球孕产妇和新生儿发病和死亡的主要原因。
- 美国妇产科医师学会推荐不对妊娠期高血压和无严重特征的子痫前期使用降压药(血压<160/110 mm Hg)。
- CHAP试验显示治疗非严重慢性高血压有益后,出现了将降压治疗用于非严重妊娠期高血压和无严重特征子痫前期的「适应证蔓延」。
核心结论
- 作者认为,在广泛使用降压药物治疗妊娠期高血压或无严重特征的子痫前期之前,必须开展一项确定性试验。
- 作者认为,在缺乏确定性试验和明确安全方案的情况下对该人群使用降压治疗可能有害,最好情况下其获益也难以评估,并可能干扰生成改变实践指南的确定性证据。
研究设计与样本
- 本文为论述性文章,未报告系统检索范围或样本量。
主要发现
- 妊娠期高血压疾病,包括妊娠期高血压和子痫前期,影响约13%的所有妊娠。
- 美国妇产科医师学会基于缺乏支持治疗的1级证据以及掩盖疾病进展或导致胎儿不良影响(如生长受限)的理论风险,推荐不对妊娠期高血压和无严重特征的子痫前期使用降压药(血压<160/110 mm Hg)。
- CHAP试验显示治疗非严重慢性高血压有益后,观察到「适应证蔓延」,即将降压药物用于治疗妊娠期高血压和无严重特征子痫前期中的非严重高血压。
关键数值与推荐
- 美国妇产科医师学会推荐不对妊娠期高血压和无严重特征的子痫前期使用降压药(血压<160/110 mm Hg)。
- CHAP试验显示治疗非严重慢性高血压有益。
临床怎么用
- 作者认为,在广泛使用降压药物治疗妊娠期高血压或无严重特征的子痫前期之前,必须开展一项确定性试验。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hypertensive disorders of pregnancy, including gestational hypertension and preeclampsia, affect approximately 13% of all pregnancies and are a major cause of maternal and neonatal morbidity and mortality worldwide. Although the treatment of preeclampsia with severe features has been well established on the basis of randomized controlled data, international society guidelines vary on the treatment of gestational hypertension and preeclampsia without severe features. The American College of Obstetricians and Gynecologists recommends against the use of antihypertensive agents for nonsevere hypertension (blood pressure of <160/110 mm Hg) in both gestational hypertension and preeclampsia without severe features given a lack of level 1 evidence in support of treatment and the theoretical risk of masking of disease progression or causing adverse fetal effects, such as growth restriction. However, with the publication of the Chronic Hypertension in Pregnancy trial, (CHAP) which demonstrated the benefit of treatment of nonsevere chronic hypertension, "indication creep" or the application of a treatment outside the population of proven benefit is being observed with the use of antihypertensive medication for the treatment of nonsevere hypertension in gestational hypertension and preeclampsia without severe features. The use of antihypertensive treatment in this population without a definitive trial and no clearly defined safety protocols is potentially dangerous and could, at worst, lead to maternal and fetal harm or, at best, provide benefit in ways that are hard to assess and, thus, interfere with efforts to generate definitive evidence to change practice guidelines, denying many pregnant patients optimal care. It is imperative that a definitive trial be performed performed prior to the widespread use of antihypertensive treatment for gestational hypertension or preeclampsia without severe features.
引用
- Griffin LB, Sinkey R, Tita A, et al. Nonsevere hypertensive disorders of pregnancy and oral antihypertensive medications: an argument against use. Am J Obstet Gynecol MFM. 2024. PMID: 39586471. doi:10.1016/j.ajogmf.2024.101560
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。